In Phase A, individuals will get different doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants might be enrolled at the recognized monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase C, participants https://erickzpbmi.blog2news.com/32672834/rumored-buzz-on-abbv-744-for-small-cell-lung-cancer-research